Last reviewed: July 1, 2026

Last updated: July 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Many people wonder whether their current weight qualifies them for semaglutide treatment, but the answer goes beyond a simple threshold. Clinical guidelines recognize that GLP-1 receptor agonists like semaglutide benefit patients with a BMI of 27 or higher who have weight-related complications, or those with a BMI of 30 or higher regardless of comorbidities.

BMI Categories and Semaglutide Eligibility

Body mass index (BMI) serves as a starting point for evaluating semaglutide candidacy, though it is not the only factor. The FDA-approved indication for semaglutide in weight management includes patients with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. BMI is calculated by dividing weight in kilograms by height in meters squared, creating a standardized measure across different body types.

However, BMI has limitations because it does not account for muscle mass, bone density, or fat distribution patterns. Two individuals with identical BMIs may have very different metabolic profiles and treatment needs. PlexusDx recognizes these nuances and evaluates candidates based on comprehensive health assessments rather than BMI alone, ensuring that treatment recommendations align with each person's unique physiology and goals.

Weight-Related Health Conditions That Support Semaglutide Use

The presence of weight-linked health problems often makes semaglutide appropriate even at lower BMI levels. Conditions including type 2 diabetes, hypertension, dyslipidemia (abnormal cholesterol), sleep apnea, and osteoarthritis all increase the clinical value of GLP-1 therapy. When weight loss occurs, many patients experience improvements in blood sugar control, blood pressure readings, and joint pain—benefits that extend beyond the scale.

Cardiovascular risk factors strengthen the case for semaglutide intervention. Patients with a history of heart disease, stroke, or significant family history of early cardiac events may benefit from weight reduction through GLP-1 therapy, even if their BMI falls just above the 27 threshold. PlexusDx clinicians review complete medical histories to identify these interconnected health patterns and customize treatment plans accordingly.

How Genetics Influence Your Semaglutide Response

Not all individuals respond identically to semaglutide, and genetic variation plays a measurable role in treatment outcomes. Specific variants in the GLP-1 receptor gene (GLP1R rs6923761), the GIPR gene (rs1800437), and metabolic genes like FTO (rs9939609) influence how effectively semaglutide reduces appetite and promotes weight loss. Some people experience rapid, sustained weight reduction, while others see more gradual changes—differences rooted partly in their genetic makeup.

PlexusDx offers the Precision Peptide Genetic Test, which maps 14 metabolic pathways and analyzes 150+ genetic insights related to peptide therapy response. This test, available for $99 after the first month of treatment, helps identify which GLP-1 approach may work best for your body. Understanding your genetic predispositions allows for smarter, more personalized dosing and medication selection, making the $149/month starting cost of compounded semaglutide injection work harder for your results.

Beyond Weight: Evaluating True Semaglutide Candidacy

True candidacy for semaglutide extends beyond weight and BMI to include metabolic health, eating behavior patterns, and realistic treatment goals. Patients who struggle with constant hunger, cravings, or binge eating often see the most dramatic benefits because semaglutide directly addresses appetite regulation in the brain. Conversely, individuals whose weight challenges stem primarily from medication side effects or untreated hormonal imbalances may need different interventions first.

PlexusDx takes a multi-layered approach to candidacy assessment, reviewing not only current weight and BMI but also metabolic markers, medication history, family patterns, and lifestyle factors. This comprehensive evaluation ensures that patients starting compounded semaglutide injection (beginning at $149/month) or other GLP-1 therapies are genuinely positioned to succeed. No insurance is required, all 50 states are served, and HSA/FSA funds are accepted, removing barriers to access for qualified candidates.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum weight or BMI to qualify for semaglutide?

A BMI of 30 or higher generally qualifies, or a BMI of 27 or higher with a weight-related health condition. However, individual circumstances vary. PlexusDx evaluates the complete clinical picture rather than relying on a single number, ensuring treatment fits your specific health profile.

Does semaglutide work if I only have a BMI between 25 and 27?

While not the standard indication, some patients with BMI 25–27 may benefit if they have significant metabolic dysfunction, strong family history of diabetes or heart disease, or severe eating behavior challenges. PlexusDx clinicians can discuss whether compounded semaglutide injection or another GLP-1 therapy may be appropriate for your situation.

Can I get compounded semaglutide if I don't have a comorbid condition?

Yes. A BMI of 30 or higher qualifies regardless of comorbidities. PlexusDx serves all 50 states without requiring insurance, and compounded semaglutide injection starts at $149/month, making this option accessible to candidates across the country.

Does the Precision Peptide Genetic Test determine if I qualify for semaglutide?

The test does not change baseline eligibility criteria, but it identifies genetic variants affecting GLP-1 receptor function, appetite pathways, and metabolic genes, helping optimize which medication and dose work best for you. The $99 test is added after your first month of treatment with PlexusDx.

What if I have tried semaglutide before and didn't lose weight?

Previous poor response may reflect inadequate dosing, insufficient treatment duration, or genetic factors affecting GLP-1 pathway sensitivity. PlexusDx's genetic testing and precision dosing approach, combined with licensed 503A compounding quality, can reveal why prior attempts underperformed and chart a more effective path forward.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves